These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35743746)

  • 21. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS; Chen JB; Yang WC
    Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
    Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients.
    Helal I; Elkateb H; Hedri H; Hajri M; Hamida FB
    Saudi J Kidney Dis Transpl; 2016; 27(6):1162-1167. PubMed ID: 27900961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.
    Akizawa T; Sato Y; Ikejiri K; Kanda H; Fukagawa M
    Kidney Int Rep; 2021 Sep; 6(9):2371-2380. PubMed ID: 34514198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and Acceptability of mHealth Interventions for Managing Hyperphosphatemia in Patients Undergoing Hemodialysis.
    St-Jules DE; Woolf K; Goldfarb DS; Pompeii ML; Li H; Wang C; Mattoo A; Marcum ZA; Sevick MA
    J Ren Nutr; 2021 Jul; 31(4):403-410. PubMed ID: 33160812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.
    Lopes AA; Tong L; Thumma J; Li Y; Fuller DS; Morgenstern H; Bommer J; Kerr PG; Tentori F; Akiba T; Gillespie BW; Robinson BM; Port FK; Pisoni RL
    Am J Kidney Dis; 2012 Jul; 60(1):90-101. PubMed ID: 22385781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia.
    Cupisti A; D'Alessandro C; Baldi R; Barsotti G
    J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Family-centered empowerment approach to optimize phosphate management among hemodialysis patients: an experimental study.
    Vasli P; Hosseini M; Nasiri M; Bakhtiari N
    BMC Nephrol; 2023 Sep; 24(1):259. PubMed ID: 37661281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
    Goldberg DI; Dillon MA; Slatopolsky EA; Garrett B; Gray JR; Marbury T; Weinberg M; Wombolt D; Burke SK
    Nephrol Dial Transplant; 1998 Sep; 13(9):2303-10. PubMed ID: 9761513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
    Bleyer AJ; Burke SK; Dillon M; Garrett B; Kant KS; Lynch D; Rahman SN; Schoenfeld P; Teitelbaum I; Zeig S; Slatopolsky E
    Am J Kidney Dis; 1999 Apr; 33(4):694-701. PubMed ID: 10196011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of education on low-phosphate diet and phosphate binder intake to control serum phosphate among maintenance hemodialysis patients: A randomized controlled trial.
    Lim E; Hyun S; Lee JM; Kim S; Lee MJ; Lee SM; Oh YS; Park I; Shin GT; Kim H; Morisky DE; Jeong JC
    Kidney Res Clin Pract; 2018 Mar; 37(1):69-76. PubMed ID: 29629279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis.
    Hung KY; Liao SC; Chen TH; Chao MC; Chen JB
    Ther Apher Dial; 2013 Feb; 17(1):72-7. PubMed ID: 23379497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.